Next 10 |
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high co...
2024-05-21 16:00:07 ET Balaji Prasad from Barclays issued a price target of $20.00 for ALVO on 2024-05-21 14:22:00. The adjusted price target was set to $20.00. At the time of the announcement, ALVO was trading at $13.76. The overall price target consensus is at $13.50 w...
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product Alvotech (NASDAQ: ALVO), a global biotech compa...
2024-05-21 08:39:19 ET More on Alvotech, Dr. Reddy's, etc. Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech (ALVO) Q4 2023 Earnings Call Transcript Teva, Alvotech...
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product HYDERABAD, India and REYKJAVIK, Iceland, May ...
CXApp Inc. (CXAI) is expected to report for quarter end 2024-03-31 Purple Biotech Ltd. (PPBT) is expected to report $-0.15 for Q1 2024 AutoZone Inc. (AZO) is expected to report $35.72 for Q3 2024 Turkcell Iletisim Hizmetleri AS (TKC) is expected to report for Q1 2024 Orkla ASA ADR...
2024-05-21 06:51:13 ET More on AbbVie, Alvotech, etc. AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript) Teva Pharmaceutical: 6 Takeaways Fr...
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira ® REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvote...
REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2024, ...
REYKJAVIK, Iceland, May 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be participating in the upcoming BofA Securities ...
News, Short Squeeze, Breakout and More Instantly...
Alvotech Company Name:
ALVO Stock Symbol:
NASDAQ Market:
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high co...
2024-05-21 16:00:07 ET Balaji Prasad from Barclays issued a price target of $20.00 for ALVO on 2024-05-21 14:22:00. The adjusted price target was set to $20.00. At the time of the announcement, ALVO was trading at $13.76. The overall price target consensus is at $13.50 w...
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product Alvotech (NASDAQ: ALVO), a global biotech compa...